GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » ROCE %

DT&CRO Co (XKRX:383930) ROCE % : 104.28% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is DT&CRO Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. DT&CRO Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 104.28%.


DT&CRO Co ROCE % Historical Data

The historical data trend for DT&CRO Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DT&CRO Co ROCE % Chart

DT&CRO Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
- 53.20 15.86 -37.24 -0.34

DT&CRO Co Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.04 -42.72 -52.53 -19.81 104.28

DT&CRO Co ROCE % Calculation

DT&CRO Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-154.024/( ( (59847.891 - 15695.691) + (81085.699 - 34185.411) )/ 2 )
=-154.024/( (44152.2+46900.288)/ 2 )
=-154.024/45526.244
=-0.34 %

DT&CRO Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=43474.732/( ( (76744.798 - 40262.901) + (81085.699 - 34185.411) )/ 2 )
=43474.732/( ( 36481.897 + 46900.288 )/ 2 )
=43474.732/41691.0925
=104.28 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DT&CRO Co  (XKRX:383930) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


DT&CRO Co ROCE % Related Terms

Thank you for viewing the detailed overview of DT&CRO Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


DT&CRO Co Business Description

Traded in Other Exchanges
N/A
Address
28, Baengnyeong-ro 20beon-gil, 2nd, 3rd, 4th floor, Na-dong, Cheoin-gu, Gyeonggi-do (Yubang-dong), Yongin-si, KOR, 17042
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.

DT&CRO Co Headlines

No Headlines